Pipeline

Life sciences are radically improving the chances of treatment, even for disease that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.
——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Platform - AssetIndication
Phase 1
Phase 2
Phase 3
Post-Market
Ophtha - NGFFront-of-the-eye: Neurotrophic Keratitis
Ophtha - NGFFront-of-the-eye: Sjogren-related Dry Eye
Ophtha - NGF IntravitrealBack-of-the-eye
NETosis - ReparixinCommunity Acquired Pneumonia (CAP)
NETosis - ReparixinAcute Respiratory Distress Syndrome (ARDS)
NETosis - LadarixinType 1 Diabetes – Early Onset
NETosis - LadarixinType 1 Diabetes – Insulin resistant
Primary Care - KLS-GabaLow-back pain
Ophtha - NGF
Indication: Front-of-the-eye: Neurotrophic Keratitis
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Ophtha - NGF
Indication: Front-of-the-eye: Sjogren-related Dry Eye
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Ophtha - NGF Intravitreal
Indication: Back-of-the-eye
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Reparixin
Indication: Community Acquired Pneumonia (CAP)
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Reparixin
Indication: Acute Respiratory Distress Syndrome (ARDS)
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Ladarixin
Indication: Type 1 Diabetes – Early Onset
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

NETosis - Ladarixin
Indication: Type 1 Diabetes – Insulin resistant
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Primary Care - KLS-Gaba
Indication: Low-back pain
Project Status:
  • Phase 1:

  • Phase 2:

  • Phase 3:

  • Post-Market:

Latest Publications

Oncology
Sars-Cov-2
Ophthalmology
Pain & Antiflammation
Preclinical Programs

The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance

16/12/2022
Authors: Mara Zippoli, Anna Ruocco, Rubina Novelli, Francesca Rocchio, Martina Sara Miscione, Marcello Allegretti, Maria Candida Cesta, Pier Giorgio Amendola

CXCR1/2dual inhibitor Ladarixin reduces tumor burden and promotes immunotherapy response in pancreatic cancer

16/11/2022
Authors: Geny Piro, Carmine Carbone, Antonio Agostini, Annachiara Esposito, Maria De Pizzol, Rubina Novelli, Marcello Allegretti, Andrea Aramini, Alessia Caggiano, Alessia Granitto, Francesco De Sanctis, Stefano Ugel, Vincenzo Corbo, Maurizio Martini, Rita Teresa Lawlor, Aldo Scarpa, Giampaolo Tortora

The Spike Mutants website: a worldwide used resource against SARS-CoV-2

28/10/2022
Authors: Isabella Romeo, Ingrid Guarnetti Prandi, Emanuela Giombini, Cesare Ernesto Maria Gruber, Daniele Pietrucci, Stefano Borocci, Nabil Abid, Anna Fava, Andrea R. Beccari, Giovanni Chillemi, Carmine Talarico
Published in:
MDPI – IJMS
SARS-CoV-2

"We must always return to basic science with fresh new eyes."

Marcello Allegretti,

Chief Scientific Officer